Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients.
Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients, according to a study.
The study included 4,966 patients with newly diagnosed gout: 2,483 on allopurinol and 2,483 not on the drug. Subjects were matched for age, gender, diabetes, hypertension, hyperlipidemia, and atrial fibrillation.
After a median follow-up of 5.2 years, the allopurinol group had a modest 20% increase in cardiovascular risk compared with the non-allopurinol group, Victor C. Kok, MD, of Kuang Tien General Hospital, Shalu, Taichung, Taiwan, and colleagues reported online in PLoS One (9:e99102). This increased to 25% after adjusting for chronic kidney disease, uremia, and gastric ulcers.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.